Summary of Product Characteristics Updated 20-Feb-2019 | Torbay & South Devon NHS Foundation Trust
Morphine Sulfate 1mg in 1mL Solution for Injection.
1mL contains 1mg of Morphine Sulfate (0.1% w/v)
Each 1mL ampoule contains 1mg of morphine sulfate and 3.6mg of sodium
Each 5mL ampoule contains 5mg of morphine sulfate and 18 mg of sodium
Each 10mL ampoule contains 10mg of morphine sulfate and 36mg of sodium.
Each 50mL vial contains 50mg of morphine sulfate and 180mg of sodium.
Solution for injection.
Morphine Sulfate Solution for Injection is indicated for the relief of moderate to severe pain. Morphine is used especially in pain associated with cancer, myocardial infarction and surgery. Morphine also helps to relieve the anxiety and insomnia which may be associated with severe pain.
Adults and children over 12 years:
Morphine Sulfate Solution for Injection is formulated for use by the intravenous route in Patient Controlled Analgesia (PCA) systems. PCA, which permits adjustment of dosage according to the patient's individual needs, must only be carried out in departments and by staff who are trained and have experience of the system. Patient selection for the use of PCA must ensure that the patient is capable of understanding and following the instructions of the medical/nursing staff. The specific department or unit protocols must be covered to ensure aseptic transfer of the contents of the ampoule or vial to the PCA system.
There is a considerable variation in analgesic requirements among patients and therefore individualised treatment strategies are required. Dosage should be based on the severity of the pain and the response and opiate tolerance of the patient.
Loading doses of typically between 1mg and 10mg (maximum 15mg) of morphine sulfate may be given by intravenous infusion over four or five minutes. The loading dose used will depend upon the patient's diagnosis and condition.
PCA demand dose
An initial demand dose of 1mg Morphine Sulfate Solution for Injection with a lockout period of 5 to 10 minutes is recommended. Dosages may vary depending on the loading dose, the tolerance and condition of the patient, and whether a background infusion of morphine sulfate is being given.
The patient should be specifically monitored for pain, sedation and respiratory rate during the first few hours of treatment to ensure that the dosage regimen is suitable.
The duration of treatment should be kept to a minimum, although dependence and tolerance are not generally a problem when morphine is used legitimately in patients with opioid-sensitive pain.
Use in children:
Not recommended for children under 12 years.
Use in the elderly:
Morphine doses need to be reduced in elderly patients.
Discontinuation of therapy
An abstinence syndrome may be precipitated if opioid administration is suddenly discontinued. Therefore the dose should be gradually reduced prior to discontinuation.
Morphine Sulfate Solution for Injection should not be given to patients with known hypersensitivity to morphine or other opioid preparations. Use of Morphine Sulfate Solution for Injection is also contraindicated in patients with respiratory depression; obstructive airways disease; excessive bronchial secretions; during a bronchial asthma attack or in heart failure secondary to chronic lung disease; head injury; raised intra-cranial pressure; coma; convulsion disorders; ulcerative colitis; in presence of a risk of paralytic ileus; biliary and renal tract spasm and acute alcoholism; phaeochromocytoma.
Morphine Sulfate Solution for Injection should not be given to patients with moderate to severe renal impairment (glomerular filtration rate <20mL/min) or with severe or acute liver failure.
Morphine Sulfate Solution for Injection is contraindicated in patients receiving monoamine oxidase inhibitors or within two weeks of discontinuing such treatment. Use of Morphine Sulfate Solution for Injection during pregnancy or lactation is not recommended.
As with other narcotics, a dose reduction may be appropriate in elderly patients, in patients with hypothyroidism, renal and chronic hepatic disease.
Morphine Sulfate Solution for Injection should be used with caution in debilitated patients and those with Acute chest syndrome (ACS) in patients with sickle cell disease (SCD); adrenal insufficiency; hypopituitarism; prostatic hypertrophy; shock; diabetes mellitus; diseases of the biliary tract; myasthenia gravis; cardiac arrhythmias; excessive obesity; hypotension and severe cardiac failure. It should also be used with caution post-operatively following total joint arthroplasty (colonic pseudo-obstruction).
Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)
Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vaso-occlusive crisis, close monitoring for ACS symptoms is warranted.
Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs: Concomitant use of Morphine Sulfate 1mg in 1mL Solution for Injection and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Morphine Sulfate 1mg in 1mL Solution for Injection concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Hyperalgesia that does not respond to a further dose increase of morphine may occur in particular in high doses. A morphine dose reduction or change in opioid may be required.
Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.
Morphine has an abuse potential similar to other strong agonist opioids, and should be used with particular caution in patients with a history of alcohol or drug abuse.
Dependence and withdrawal (abstinence) syndrome
Use of opioid analgesics may be associated with the development of physical and/or psychological dependence or tolerance. The risk increases with the time the drug is used, and with higher doses. Symptoms can be minimised with adjustments of dose or dosage form, and gradual withdrawal of morphine. For individual symptoms, see section 4.8.
Decreased Sex Hormones and increased prolactin
Long-term use of opioid analgesics may be associated with decreased sex hormone levels and increased prolactin. Symptoms include decreased libido, impotence or amenorrhea.
This medicinal product contains 3.6mg sodium per 1mL, equivalent to 0.2 % of the WHO recommended maximum daily intake of 2g sodium for an adult.
Concomitant or recent use of monoamine oxidase inhibitors with morphine is contraindicated since interactions have been reported, resulting in CNS excitation or depression with hyper- or hypotensive crises.
The CNS depressant effects of morphine are increased by the co-administration of CNS depressants including alcohol, anaesthetics, muscle relaxants, hypnotics, sedatives, tricyclics, neuroleptics and phenothiazines. Hyperpyrexia and CNS toxicity may result from an opiate selegiline combination. Sedative medicines such as benzodiazepines or related drugs: The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4)
The analgesic effects of opioids tend to be enhanced by the concomitant administration of dexamfetamine, hydroxyzine and some phenothiazines (although the latter may also cause respiratory depression). Morphine may reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. The combination of morphine with anticholinergics may enhance the constipatory effect and urinary retention.
Cimetidine and ranitidine appear to interfere with the metabolism of morphine and the metabolism and excretion of morphine may be inhibited by disulfiram. Increased morphine levels may result from the co-administration of cisapride. Metoclopramide and domperidone may antagonise morphine's gastrointestinal effects and metoclopramide enhances its sedative effect. Ciprofloxacin concentration may be reduced and mexiletine absorption delayed by co-administered opiate. Animal data suggest that propranolol may increase the toxicity of opioids. Ritonavir can induce the formation of metabolising enzymes made in the liver and can cause increased metabolism of morphine sulfate which can reduce the clinical efficacy of the analgesic.
Both antipsychotics and morphine sulfate have sedative effects which can be addictive when co-administered.
Co-administration of morphine sulfate with esmolol results in a slight increase in the esmolol levels, but the clinical implications of this increase are not considered very significant.
Animal studies have shown that morphine may reduce fertility (see 5.3. preclinical safety data).
Newborns whose mothers received opioid analgesics during pregnancy should be monitored for signs of neonatal withdrawal (abstinence) syndrome. Treatment may include an opioid and supportive care.
Morphine has been shown to suppress lactation, although morphine is secreted in breast milk and may cause respiratory depression in the infant.
Morphine may modify the patient's reactions to a varying extent depending on the dosage and individual susceptibility. Ambulatory patients should be warned not to use machines.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely.
The side-effects most commonly seen with morphine and other opioids are respiratory depression, nausea, vomiting, constipation, drowsiness and confusion. With long term use these symptoms generally lessen, although constipation frequently persists.
The following adverse effects are from published literature and frequencies are not known.
Restlessness, mood changes, hallucinations, delirium, disorientation, excitation, agitation, sleep disturbance, dependence.
Nervous system disorders
Headache, vertigo, euphoria, dsyphoria, dizziness, taste disturbances, seizures, paraesthesia, raised intracranial pressure, hyperhidrosis, allodynia and hyperalgesia (see section 4.4).
Long term use of opioid analgesics can cause adrenal insufficiency. Exacerbation of pancreatitis.
Visual disturbances, nystagmus, miosis.
Ear and Labyrinth disorders
Bradycardia, tachycardia, palpitations, hypotension, hypertension, syncope.
Orthostatic hypotension, facial flushing, oedema.
Dry mouth, dyspepsia, paralytic ileus, abdominal pain, anorexia.
Immune system disorders
Anaphylactoid reactions. Anaphylactic reactions to morphine have been reported rarely.
Musculoskeletal, connective tissue and bone disorder
Muscle fasciculation, myoclonus, rhabdomyolysis, muscle rigidity.
Renal and urinary disorders
Difficult micturition, ureteric spasm, urinary retention.
Reproduction and sexual disorders
Long term use of opioid analgesics can cause hypogonadism in both men and women. This can lead to amenorrhoea, reduced libido, infertility, depression and erectile dysfunction.
Bronchospasm (in association with anaphylaxis), inhibition of cough reflex.
Skin and subcutaneous tissue disorders
Rashes, urticaria, pruritus.
General disorders and administration site conditions.
Sweating, hypothermia, malaise, asthenia, pain and irritation at the injection site, drug withdrawal (abstinence) syndrome.
Long Term Use
Tolerance and psychological and physical dependence may occur. Decreased potency may be experienced. High doses may produce respiratory depression and hypotension, with deepening coma. Convulsions may occur particularly in infants.
Dysphoric mood and anxiety
Drug dependence and withdrawal (abstinence) syndrome
Use of opioid analgesics may be associated with the development of physical and/or psychological dependence or tolerance. An abstinence syndrome may be precipitated when opioid administration is suddenly discontinued or opioid antagonists administered, or can sometimes be experienced between doses. For management, see 4.4.
Physiological withdrawal symptoms include: Body aches, tremors, restless legs syndrome, diarrhoea, abdominal colic, nausea, flu-like symptoms, tachycardia and mydriasis. Psychological symptoms include dysphoric mood, anxiety and irritability. In drug dependence, “drug craving” is often involved.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The signs of morphine overdose consist of pin-point pupils, respiratory depression, Pneumonia aspiration and hypotension. Death may occur from respiratory failure. Circulatory failure and deepening coma may develop in severe cases and death may ensue. Less severe cases may be manifest by nausea, vomiting, tremor, dysphoria, hypothermia, hypotension, confusion and sedation. Rhabdomyolysis progressing to renal failure can also be a consequence of overdosage.
It is vital to maintain and support respiration and circulation. The specific opioid antagonist naloxone should be employed for the reversal of coma and restoration of spontaneous respiration. 400 micrograms of naloxone should be administered intravenously, repeated at 2 - 3 minute intervals as necessary up to a maximum dose of 10mg.
Morphine acts as a competitive agonist at opiate receptors in the CNS, particularly mu and to a lesser extent kappa receptors. Activity at the mu-1 subtype receptor is thought to mediate analgesia, euphoria and dependence whilst activity at the mu-2 receptor is thought to be responsible for respiratory depression and inhibition of gut motility. Action at the kappa receptor may mediate spinal analgesia. The analgesic action of morphine is effective at several spinal and supraspinal sites.
Onset of action is rapid following parenteral administration of morphine with peak analgesic effect occurring within 20 minutes via the intravenous route.
Morphine is widely distributed in the body, with an apparent volume of distribution of 2 - 3Lkg-1. Due to its relatively hydrophilic nature, morphine does not readily cross the blood-brain barrier although it is detectable in the cerebrospinal fluid.
Morphine is extensively metabolised by the liver. Renal glucuronidation also takes place. The major metabolite, quantitatively, is morphine-3-glucronide although morphine-6-glucuronide is significant in terms of potency.
The metabolites are excreted mainly via the renal route.
The toxicological profile of morphine in animals has not been systematically identified as a result of its established widespread clinical use. Recent animal studies have confirmed some targets for morphine toxicity. A nephrotoxic action has been reported in rats following subcutaneous administration of relatively high levels (up to 96mg/kg) of morphine. In male rats, reduced fertility and chromosomal damage in gametes have been reported. Adverse effects of morphine on development of the foetus and newborn have been confirmed in rats and mice. Morphine has been shown to reduce the release of LH from the pituitary causing reductions in serum testosterone levels, reduction in the weight of secondary sex organs and reductions in spermatogenic cell populations. The adverse effects of morphine sulfate in both males and females are consistent with recent findings that morphine exhibits significant genotoxic actions in several in vivo test systems. Immunotoxicity associated with morphine treatment has been reported in animal tests for several parameters which provide possible mechanisms for decreased resistance to a range of infections. Evidence suggests that part of this effect may be mediated via release of endogenous corticosterone.
Water for Injections
Morphine Sulfate Solution for Injection should not be mixed with other preparations.
Morphine salts are incompatible with aminophylline, sodium salts of barbiturates and phenytoin, aciclovir sodium, furosemide, heparin sodium, pethidine HCl, prochlorperazine edisylate and promethazine HCl.
Physicochemical incompatibility (formation of precipitates) has been demonstrated between solutions of morphine sulfate and 5- fluorouracil.
Keep away from light. Store below 25°C.
Clear glass ampoules of 1mL, 5mL or 10mL volume or vials of 50mL volume, with bromobutyl rubber stoppers and tamper-evident aluminium caps. The product is packed into cartons containing 10 ampoules, 1 vial or 10 vials. Both pack sizes of vials may not be available at the same time.
Morphine Sulfate Solution for Injection is for use as presented (1mg mL-1) in IV PCA devices.
Torbay and South Devon NHS Foundation Trust
Devon, TQ4 7FG
Wilkins Drive, Paignton, TQ4 7FG
+44 (0)1803 660000
+44 (0)7824 889143
+44 (0)1803 664707
+44 (0)1803 664707
+44 (0)1803 664354
+44 (0)1803 664 354